C3 and paroxysmal nocturnal hemoglobinuria: The inhibition of activated complement has already demonstrated notable success in clinical practice, for example, C3 and/or C5 inhibitors for paroxysmal nocturnal hemoglobinuria (PNH) [30] or targeting C1s in cold agglutination disease [31].